Freedom performs better with ticlopidine
This article was originally published in Clinica
Executive Summary
Global Therapeutics' Freedom stent performs poorly in calcified lesions, research carried out in the EU has shown. Dr Bernard Chevallier of the Centre Cardiologique du Nord, France, presented data from the first 530 patients treated there and in Belgium up to the beginning of March. Ten percent of patients received more than one stent - bringing the total number of implants to 633. Recoil occurred in 9.3% and technical success was 96.3%, Dr Chevallier told delegates at the ACC meeting. The 21 failures were mostly in calcified lesions.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.